Raffi F, et al. Switching from an abacavir (ABC)/lamivudine (3TC)-based regimen to a single-tablet regimen of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF): Cardiovascular disease risk profile analysis from a randomized controlled study in virologically-suppressed adults. AIDS 2018.
1,3 miljoen euro voor LUMC-onderzoek naar COVID-19 en trombose
sep 2020 | Benigne hematologie, Vasculaire geneeskunde, Virale infecties